Tilavonemab
As of the edition of 20 October 2026, Tilavonemab is an antibody: stopped in 2021; acts on MAPT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 7, 3 stopped early
- Disease areas
- Nervous system; Eye; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Tilavonemab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAPT | Microtubule-associated protein tau | P10636 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 4 | 1 | 0 | 3 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| C2N Diagnostics | Lead sponsor of trials | 2015 to now |
| AbbVie | Lead sponsor of trials |